Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

9904	Companies
199560	Keywords
130432	Articles
106067	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 07/02/2024 at 13:30, 1 year 7 months ago

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Moderna, Inc. awarded $176 million to accelerate mRNA-based pandemic influenza vaccine development through a Consortium funded by BARDA. Collaboration aims to enhance global public health preparedness

Moderna Inc. MRNA Technology BARDA Pandemic Influenza Vaccine Global Public Health
BRIEF

published on 06/28/2024 at 13:05, 1 year 7 months ago

EMA Committee Recommends Marketing Authorization for Moderna's RSV Vaccine

Moderna MRNA Vaccine RSV EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 13:00, 1 year 7 months ago

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited

Moderna Inc. RSV Vaccine MRESVIA EMA CHMP MRNA-1345
BRIEF

published on 06/13/2024 at 13:05, 1 year 8 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Efficacy Data
PRESS RELEASE

published on 06/13/2024 at 13:00, 1 year 8 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna's mRNA-1283 demonstrates non-inferior COVID-19 vaccine efficacy compared to Spikevax in Phase 3 trial. Higher efficacy in adults observed. Positive interim results reported

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Spikevax
BRIEF

published on 06/10/2024 at 12:35, 1 year 8 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1083 Influenza
PRESS RELEASE

published on 06/10/2024 at 12:30, 1 year 8 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna's mRNA-1083 Phase 3 trial for flu and COVID combination vaccine elicits strong immune responses in adults 50+ & 65+. Promising results may reshape respiratory virus vaccination

COVID-19 Moderna Phase 3 Trial MRNA-1083 Flu
BRIEF

published on 06/07/2024 at 16:35, 1 year 8 months ago

Moderna Files FDA Application for JN.1 Targeting COVID-19 Vaccine

FDA COVID-19 Moderna Spikevax JN.1 Variant
PRESS RELEASE

published on 06/07/2024 at 16:30, 1 year 8 months ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Moderna prepares to ship Spikevax 2024-2025 formula pending FDA approval for SARS-CoV-2 variant JN.1. CEO emphasizes importance of updating COVID-19 vaccines. Adverse reactions & safety info highlighted

FDA Approval COVID-19 Vaccine Moderna Spikevax 2024-2025 Adverse Reactions
BRIEF

published on 06/06/2024 at 13:05, 1 year 8 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia Selected by FDA for START Pilot Program

FDA Moderna MMA MRNA-3705 START Program

Accesswire

Published on 02/21/2026 at 00:45, 1 day 19 hours ago

Bocana Resources Corp. Extends Letter of Intent on Arizona Mining Claims for Additional Bulk Testing and Assay Review
Published on 02/21/2026 at 00:30, 1 day 19 hours ago

Redwood AI Corp. Announces Engagement for IR Services
Published on 02/20/2026 at 23:15, 1 day 20 hours ago

DigiPower X Announces Closing of Settlement
Published on 02/20/2026 at 23:00, 1 day 21 hours ago

Infinico Metals Corp. Announces Effective Date for 15-for-1 Common Share Consolidation
Published on 02/20/2026 at 22:17, 1 day 21 hours ago

Organto Foods Completes Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 02/22/2026 at 12:19, 7 hours 45 minutes ago

Elmos Semiconductor SE: Generational change initiated in the Supervisory Board
Published on 02/22/2026 at 10:09, 9 hours 55 minutes ago

Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 02/21/2026 at 12:00, 1 day 8 hours ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Published on 02/20/2026 at 18:36, 2 days 1 hour ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 2 days 1 hour ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 02/20/2026 at 19:29, 2 days ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 18:00, 2 days 2 hours ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 09:28, 2 days 10 hours ago

Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
Published on 02/20/2026 at 07:30, 2 days 12 hours ago

Announcement of share buyback in the context of a share purchase plan
Published on 02/20/2026 at 07:30, 2 days 12 hours ago

EURAZEO COMPLETES THE SALE OF EX NIHILO TO L CATTERTON

View all LES ECHOS COMFI WIRE